Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$62.10 USD
-1.92 (-3.00%)
Updated May 10, 2024 04:00 PM ET
After-Market: $62.00 -0.10 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$62.10 USD
-1.92 (-3.00%)
Updated May 10, 2024 04:00 PM ET
After-Market: $62.00 -0.10 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Zacks News
Zacks.com featured highlights: Milacron Holdings, Rice Midstream Partners, Calavo Growers, Cytokinetics and II-VI
by Zacks Equity Research
Zacks.com featured highlights: Milacron Holdings, Rice Midstream Partners, Calavo Growers, Cytokinetics and II-VI
Falling Earnings Estimates Signal Weakness Ahead for Gilead Sciences (GILD)
by Zacks Equity Research
Gilead Sciences (GILD) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
5 Profitability Stocks to Make the Most of Trump Bump
by Zacks Equity Research
Net income ratio selects the best profitable company on the back of Trump-led rally.
3 Reasons Why Cytokinetics (CYTK) is a Great Momentum Stock
by Zacks Equity Research
Cytokinetics (CYTK) may prove to be a fresh pick that has potential to move in the right direction and is seeing momentum.
Zacks.com featured highlights: Calavo Growers, Cytokinetics, Sucampo Pharmaceuticals, State National and CryoLife
by Zacks Equity Research
Zacks.com featured highlights: Calavo Growers, Cytokinetics, Sucampo Pharmaceuticals, State National and CryoLife
Cytokinetics (CYTK): An Off-the-Radar Potential Winner
by Zacks Equity Research
Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for Cytokinetics (CYTK) and that now might be an interesting buying opportunity.
5 Profitable Stocks to Buy for Great Returns
by Zacks Equity Research
Net income ratio gives us the exact profit level of a company and reflects the percentage of net income to total sales revenue.
New Strong Buy Stocks for December 28th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
3 Biotech Stocks to Turn the Tide This Earnings Season
by Zacks Equity Research
The biotech sector has strong fundamentals, and healthy product pipelines.
4 Biotech Stocks Looking Good this Earnings Season
by Zacks Equity Research
the market sentiment seems to be improving driven by upgraded guidance, product approvals and encouraging pipeline updates.
5 Stocks Rocketing to New Highs
by David Bartosiak
These 5 stocks are breaking out to new highs on good volume